Long-Term Efficacy of EUS-Guided Gallbladder Drainage for Acute Cholecystitis: A Meta-Analysis
Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) is a highly effective and durable treatment for acute cholecystitis, maintaining high success rates even after more than a year of follow-up. A systematic review and meta-analysis led by Canakis et al. found that the procedure achieves a clinical success rate of 94.3% in patients at high risk for surgical complications, with few reported side effects among 701 study participants.
The average stent patency following EUS-GBD procedures was recorded at 418.8 days, highlighting the long-term viability of the drainage method for patients requiring non-surgical intervention.
Clinical Success and Long-term Outcomes
Researchers analyzed 18 studies involving 701 patients to assess the long-term performance of EUS-GBD, with data collected up to September 2024. The findings confirm a technical success rate of 95.8% and a clinical success rate of 94.3%. These metrics suggest that the procedure remains a reliable alternative to traditional, more invasive surgeries for patients who face a high risk of complications.
Recurrence of cholecystitis after at least one year was observed in 4.2% of cases. While 19% of patients required hospital readmission within a year of the procedure, only 6% required a secondary intervention. Stent-related issues were infrequent, with 2.9% of patients requiring repeat endoscopy to address stent obstruction or occlusion.
The shift toward EUS-GBD over percutaneous transhepatic gallbladder drainage reflects a broader trend in gastroenterology toward less invasive, endoscopically managed solutions. By minimizing external incisions, clinicians can provide durable outcomes for frail patients, though the 19% readmission rate suggests that close monitoring remains essential even after a technically successful procedure.
What Happens Next?
As clinical guidelines increasingly favor EUS-GBD over percutaneous alternatives for high-risk populations, medical centers may continue to standardize this technique. Future clinical practices could see further refinements in stent technology to improve the average patency period beyond the current 418.8 days. Clinicians may also focus on identifying specific patient profiles that are most prone to the 19% readmission rate to better manage long-term recovery and minimize secondary interventions.
Frequently Asked Questions
How effective is EUS-GBD for acute cholecystitis?
According to the study by Canakis et al., EUS-GBD shows a technical success rate of 95.8% and a clinical success rate of 94.3%.
What is the risk of recurrence after one year?
The research indicates that the percentage of cholecystitis recurrence after a minimum of one year is 4.2%.
How often do patients require additional procedures?
Data shows that 6% of patients required a re-intervention, while 2.9% required a repeat endoscopy specifically due to stent obstruction or occlusion.
How might these long-term success rates influence the way surgeons approach high-risk gallbladder patients in the coming years?